...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrine journal >Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus
【24h】

Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus

机译：米格列醇联合强化胰岛素治疗对血糖控制的影响，特别涉及1型糖尿病的肠降血糖素反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To determine whether miglitol administration improves glycemic control and reduces the frequency of hypoglycemia in type 1 diabetes mellitus (T1DM) patients treated with intensive insulin therapy, we analyzed the effect of miglitol on daily insulin doses, body weight, hypoglycemia, and incretin hormone responses during meal tolerance tests (MTT). Eleven T1DM subjects (21-77 years) undergoing intensive insulin therapy, took 25 mg (weeks 0-4) and 50 mg miglitol (weeks 4-12) thrice daily, immediately before meals. At weeks 0 and 12, 9 of 11 subjects underwent MTT. In present study, mean HbAlc, glycoalbumin, and 1,5-anhydroglucitol levels were significantly improved. The blood glucose level 1 h after dinner was significantly lower at week 12 than at week 0 (p = 0.008). From week 0 to 12, there was a significant decrease in the body mass index (BMI; p = 0.0051), frequency of preprandial hypoglycemic events (p - 0.012), and daily bolus insulin dosage (p = 0.018). The change in active glucagon-like peptide-1 (GLP-1) at 120 min significantly increased at week 12 (p = 0.015). The change in total glucose-dependent insulinotropic peptide (GIP) significantly decreased in the MTT at week 12. These results demonstrate that addition of miglitol on intensive insulin therapy in T1DM patients has beneficial effects on reducing BMI, bolus and total insulin dosage, and frequency of preprandial hypoglycemic events. MTT findings suggest that this combination therapy improves blood glucose control by delaying carbohydrate absorption and modifying the responses of incretins, GIP, and GLP-1.
机译：为了确定米格列醇的施用是否能改善接受强化胰岛素治疗的1型糖尿病（T1DM）患者的血糖控制并降低低血糖的发生率，我们分析了米格列醇对每日胰岛素剂量，体重，低血糖和肠降血糖素激素反应的影响膳食耐受性测试（MTT）。接受强化胰岛素治疗的11名T1DM受试者（21-77岁）每天三餐，分别在饭前服用25 mg（0-4周）和50 mg miglitol（4-12周）。在第0周和第12周，对11位受试者中的9位进行了MTT。在本研究中，HbAlc，糖蛋白和1,5-脱水葡萄糖醇的平均水平显着提高。饭后1小时的血糖水平在第12周时显着低于第0周（p = 0.008）。从第0周到第12周，体重指数（BMI; p = 0.0051），餐前降糖事件发生频率（p-0.012）和每日推注胰岛素剂量（p = 0.018）显着下降。在第12周，活性胰高血糖素样肽1（GLP-1）的变化在120分钟时显着增加（p = 0.015）。在第12周时，MTT中总葡萄糖依赖性促胰岛素肽（GIP）的变化显着降低。这些结果表明，在T1DM患者中，在强化胰岛素治疗中添加米格列醇对降低BMI，推注和总胰岛素剂量以及频率具有有益的作用。餐前降糖事件。 MTT的发现表明，这种联合疗法可通过延迟碳水化合物的吸收并改善肠降血糖素，GIP和GLP-1的反应来改善血糖控制。

著录项

  • 来源
    《Endocrine journal》 |2011年第10期|p.869-877|共9页
  • 作者

    Etsuko Nagai; Tomoyuki Katsuno; Jun-ichiro Miyagawa; Kosuke Konishi; Masayuki Miuchi; Fumihiro Ochi; Yoshiki Kusunoki; Masaru Tokuda; Kazuki Murai; Tomoya Hamaguchi; Mitsuyoshi Namba;

  • 作者单位

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Innovative Diabetes Treatment, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

    Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    glucagon-like peptide-1 (GLP-1); glucose-dependent insulinotropic peptide (GIP); glucagon; alpha- glucosidase inhibitor;

    机译：胰高血糖素样肽-1（GLP-1）;葡萄糖依赖性促胰岛素肽（GIP）;胰高血糖素α-葡萄糖苷酶抑制剂;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号